Amoy Diagnostics News

Ed Biotech (300685): Significant increase in 24Q3 performance was accompanied by multiple indications for diagnostic products approved by Japan

everbrightOct 29 16:46

Ed Biotech (300685): Performance is in line with expectations, innovation progresses steadily

gtjaOct 24 14:22

Ed Biotech (300685): Hengqiang, the leading leader in tumor companion diagnosis

Sep 2 16:56

Ed Biotech (300685): Revenue in the second quarter increased 17.5% year-on-year, and cooperation with innovative pharmaceutical companies continued to deepen

Aug 11 00:00

Ed Biotech (300685): Performance is in line with expectations along with steady development of leading diagnostic companies

Aug 8 07:36

Ed Biotech (300685): 24H1 performance is in line with expectations, steady growth in hospital business

Aug 8 00:00

Ed Biotech (300685): Performance continues to grow steadily, innovation and cooperation continue to expand

Jul 31 16:41

Ed Biotech (300685): 24H1 performance is in line with expectations, steady growth in hospital business

Jul 31 07:46

Ed Biotech (300685): Steady domestic growth in pharmaceutical/essential consumption, rapid business growth in overseas and pharmaceutical companies

Jul 30 16:51

Ed Biotech (300685): Net profit deducted from non-return to mother increased 26% year-on-year in the first quarter, consolidating the leading position in the industry

May 16 14:41

Ed Biotech (300685): Domestic share is expected to increase and accelerate overseas market development

Apr 25 18:31

Ed Biotech (300685): Leading companies in the regulatory development and compliance of the oncology genetic testing industry benefit from many parties

Apr 24 20:31

Ed Biotech (300685): First quarter results are in line with expectations, optimistic about the release of innovative products

Apr 24 00:00

Ed Biotech (300685): Performance has achieved steady growth, and the new product layout is expected to accelerate

Apr 23 15:21

Guoxin Securities released a research report on April 23 stating that it gave Ed Biotech (300685.SZ) a purchase rating. The main reasons for the rating include: 1) revenue surpassed 1 billion dollars for the first time, and the leading position in the hos

Zhitong FinanceApr 23 10:37

Ed Biotech (300685): Revenue increased 38% year-on-year in the fourth quarter, and insisted on using the hospital market as the main track

Apr 22 13:56

Ed Biotech (300685): Performance is in line with expectations, and compliance advantages are highlighted

Apr 18 09:36

Ed Biotech (300685): Annual results exceeded expectations and accelerated development of domestic and foreign markets

Apr 16 15:01

Ed Biotech (300685): Contrary to the trend, the performance exceeded expectations

Apr 15 21:06

Ed Biotech (300685): Net profit to mother increased 108% year-on-year in the fourth quarter, bucking the trend, demonstrating leading position

Mar 5 11:11